LY4100511 for Psoriasis

Phase 2

Recruiting

Research Sponsored by DICE Therapeutics, Inc., a wholly owned subsidiary of Eli Lilly and Company

Eligibility Criteria Checklist

Specific guidelines that determine who can or cannot participate in a clinical trial

Must have

Must be willing to discontinue topical and/or systemic therapies for psoriasis before the first dose of study intervention

Be older than 18 years old

Must not have

Have a history of erythrodermic psoriasis, generalized or localized pustular psoriasis, predominantly guttate psoriasis, or medication-induced or medication-exacerbated psoriasis

Have any known or suspected diagnosis of inflammatory conditions other than psoriasis and psoriatic arthritis, including but not limited to rheumatoid arthritis, sarcoidosis, IBD (Crohn's disease or ulcerative colitis), or systemic lupus erythematosus

Timeline

Screening 3 weeks

Treatment Varies

Follow Up baseline to week 12

Summary

This trial aims to test how safe and effective the drug LY4100511 is for adults with moderate-to-severe plaque psoriasis.

Who is the study for?

This trial is for adults with moderate-to-severe plaque psoriasis. Specific eligibility criteria are not provided, but typically participants must meet certain health standards and may be excluded based on other medical conditions or treatments.

What is being tested?

The study is testing the safety and effectiveness of a new medication called LY4100511 compared to a placebo in treating plaque psoriasis. This phase 2 trial will help determine the appropriate dose range for future studies.

What are the potential side effects?

While specific side effects of LY4100511 are not listed, common side effects for psoriasis medications can include skin irritation, headaches, fatigue, nausea, and potential impacts on liver function.

Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below

Select...

I am willing to stop my current psoriasis treatments before starting the study treatment.

Exclusion Criteria

You may be eligible for the trial if you check “No” for criteria below:

Select...

I have a history of severe psoriasis.

Select...

I have a condition like psoriasis or psoriatic arthritis, but not conditions like rheumatoid arthritis or lupus.

Select...

I have had a major worsening of my psoriasis in the last 3 months.

Select...

I am being treated with drugs that affect my immune system for psoriatic arthritis.

Timeline

Screening ~ 3 weeks3 visits

Treatment ~ Varies

Follow Up ~ baseline to week 12

Screening ~ 3 weeks

Treatment ~ Varies

Follow Up ~baseline to week 12

This trial's timeline: 3 weeks for screening, Varies for treatment, and baseline to week 12 for reporting.

Treatment Details

Study Objectives

Study objectives can provide a clearer picture of what you can expect from a treatment.

Secondary study objectives

Number of participants with one or more Adverse Event (s) (AEs), and Serious Adverse Event(s) (SAEs) considered by the by the investigator to be related to study drug administration